Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Mathematical modeling of ER-positive breast cancer treatment with AZD9496 and palbociclib

Department of Applied Mathematics, Feng Chia University, Seatwen, Taichung 40724, Taiwan

Special Issues: Mathematical modeling in medicine

Breast cancer is a heterogeneous disease. Understanding the tumor subtypes can help identify the best option of treatment. Mathematical modeling of tumor growth is a useful tool to understand the observed clinical phenomena. This work is based on a previously published mathematical model of breast cancer in MCF-7 cell line. In this paper, cancer therapy using AZD9496 and palbociclib is incorporated into the mathematical model. Numerical results produced using the mathematical model are compared with those observed in clinical and experimental studies. Numerical simulation shows that monotherapy with AZD9496 can inhibit the growth of a tumor with a restricted tumor size, monotherapy with palbociclib is ineffective, and combination therapy with AZD9496 and palbociclib can produce synergistic effect and control a larger tumor.
  Article Metrics


1. A. Pawlik, M. Słomińska-Wojewódzka and A. Herman-Antosiewicz, Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants, Eur. J. Nutr., 55 (2016), 1165-1180.    

2. J. Z. Drago, S. Chandarlapaty and K. Jhaveri, Targeting apoptosis: a new paradigm for the treatment of estrogen receptor-positive breast cancer, Cancer Discov., 9 (2019), 323-325.    

3. F. Lumachi, D. A. Santeufemia, S. M. M. Basso, Current medical treatment of estrogen receptor-positive breast cancer, World J. Biol. Chem., 6 (2015), 231.

4. A. Nardone, H. Weir, O. Delpuech, et al. The oral selective oestrogen receptor degrader SERD AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance, Br. J. Cancer, 120 (2019), 331.

5. H. M. Weir, R. H. Bradbury, M. Lawson, et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models, Cancer Res., 76 (2016), 3307-3318.    

6. V. C. Jordan, Tamoxifen resistance trumped and oral selective estrogen receptor degraders arrive, Clin. Cancer Res., 24 (2018), 3480-3482.    

7. C. De Savi, R. H. Bradbury, A. A. Rabow, et al. Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2, 3, 4, 9-tetrahydro-1H-pyrido [3,4-b]indol-1-yl) phenyl) acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist, J. Med. Chem., 58 (2015), 8128-8140.    

8. J. McCain, First-in-class CDK4/6 inhibitor palbociclib could usher in a new wave of combination therapies for HR+, HER2- breast cancer, Pharm. Ther., 40 (2015), 511.

9. E. P. Hamilton, M. R. Patel, A. C. Armstrong, et al. A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER+/HER2- advanced breast cancer, Clin. Cancer Res., 24 (2018), 3510-3518.    

10. C. Paoletti, G. Schiavon, E. M. Dolce, et al. Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial, Clin. Cancer Res., 24 (2018), 5860-5872.    

11. A. D. Leo, G. Jerusalem, L. Petruzelka, et al. Final overall survival: fulvestrant 500mg vs 250mg in the randomized confirm trial, J. Natl. Cancer Inst. 106 (2014), djt337.

12. M. Thill and M. Schmidt, Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer, Ther. Adv. Med. Oncol., 10 (2018), 1758835918793326.

13. E. Lim, J. Beith, F. Boyle, et al. Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer, Asia. Pac. J. Clin. Oncol., 14 (2018), 12-21.

14. H.-C. Wei, Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line, Clin. Cancer Res., 16 (2019), 6512-6535.

15. A. K. Gupta, S. Sharma, N. Dahiya, et al. Palbociclib: a breakthrough in breast carcinoma in women, Med. J. Armed Forces India, 72 (2016), S37-S42.

16. P. V. Sivakumar, R. Garcia, K. S. Waggie, et al. Comparison of vascular leak syndrome in mice treated with IL21 or IL2, Comparative Med., 63 (2013), 13-21.

17. J. E. Berrington, D. Barge, A. C. Fenton, et al. Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry, Clin. Exp. Immunol., 140 (2005), 289-292.    

18. H. Nawata, M. T. Chong, D. Bronzert, et al. Estradiol-independent growth of a subline of MCF-7 human breast cancer cells in culture, J. Biol. Chem., 256 (1981), 6895-6902.

19. R. Clarke, N. Brünner, B. S. Katzenellenbogen, et al. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo, Proceedings of the National Academy of Sciences, 86 (1989), 3649-3653.    

© 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved